Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). The company's pipeline includes an RNAi therapeutic, imdusiran, and an oral PD-L1 inhibitor, AB-101, both in clinical trials for cHBV treatment.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.